Evaluation of Remote Programming of Cochlear Implants in Routine Cochlear Implant Follow-up
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Recruiting
- Groupement Hospitalier Pitié Salpêtrière
-
Contact:
- Isabelle Mosnier
- Phone Number: +33142162606
- Email: isabelle.mosnier@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Ability to provide informed consent
- Ability to give feedback on hearing impressions
- Aged 18 years of age or older
Implanted with a HiResolution Bionic Ear System (HiRes 90K or HiRes 90K Advantage or HiRes Ultra or HiRes Ultra 3D) on at least one side
- Group 1 - Unilateral: no hearing device except contralateral routing of signals (CROS) device on the contralateral side
- Group 2 - Bilateral: implanted on both sides
- Group 3 - Bimodal: hearing aid on the contralateral side
- Minimum of six months of cochlear implant experience
- Minimum of one month experience with a Naída CI M or Sky CI M sound processor
- Fluent in French language
- Ability to be tested via speech perception test in noise
- Smartphone user
Exclusion Criteria:
- Clinical presentation indicative of potential implanted device malfunction
- Unrealistic expectations regarding potential benefits, risks and limitations of the investigational device as determined by the Investigator
- Unwillingness or inability of subject to comply with all investigational requirements as determined by the Investigator
Pregnancy and breast-feeding are not exclusion criteria.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Group 1
Unilateral users
|
Use of the remote programming function of Target CI v1.5 and the AB remote support application
|
|
Group 2
Bilateral users
|
Use of the remote programming function of Target CI v1.5 and the AB remote support application
|
|
Group 3
Bimodal users
|
Use of the remote programming function of Target CI v1.5 and the AB remote support application
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
50% SRT measured as signal to noise ratio in DB (French Matrix test in noise)
Time Frame: one-month chronic use of remotely fitted sound processor
|
The primary efficacy objective is to demonstrate that speech recognition in noise after remote fitting is no worse than speech recognition in noise after in-office fitting.
|
one-month chronic use of remotely fitted sound processor
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Score in the Lafon phoneme test in quiet
Time Frame: one-month chronic use of remotely fitted sound processor
|
The secondary efficacy objective is to demonstrate that speech recognition in quiet after remote fitting is no worse than speech recognition in quiet after in-office fitting.
|
one-month chronic use of remotely fitted sound processor
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ABInt-24-23
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.